India, China and Other Emerging Markets Key Prospects for Interventional Cardiac Device Manufactures

MOUNTAIN VIEW, Calif., March 18, 2014 /PRNewswire/ -- A high degree of unmet clinical needs, the rising prevalence of ailments such as coronary artery diseases and hypertension, as well as increasing disposable incomes are creating robust opportunities for emerging interventional cardiac devices in emerging countries. Although the U.S. and European markets will witness the highest growth, device manufacturers must focus on developing economies such as India and China, where the market is growing between 12 and 15 percent per annum.

New analysis from Frost & Sullivan's analysis on The Global Emerging Interventional Cardiac Devices Market finds the market earned revenue of $1.49 billion in 2013 and estimates this to reach $6.93 billion in 2020. The analysis covers devices for the following segments: transcatheter heart valves, renal denervation, bronchial thermoplasty, bioresorbable stents, and fractional flow reserve.

For complimentary access to more information on this research, please visit: http://bit.ly/1gvzpiG.

"Cardiac disorders, including atrial septal aneurysm and patent foramen ovale that have been recognized as possible risk elements for ischemic stroke, are evolving into potential markets for interventional cardiac devices worldwide," said Frost & Sullivan Advanced Medical Technologies Research Analyst Swathi Allada. "Many companies have already forayed into this sector with products cleared under Food and Drug Administration humanitarian device exemptions."

However, as with any emerging technology, the shortage of specialists restrains the use of interventional cardiac procedures. The current workforce in cardiology is insufficient to meet the escalating need across the globe. To resolve this challenge, official training programs have been set up by various academic institutions as well as companies like Edwards Lifesciences and Medtronic.

The development of these products will likely shape the overall interventional cardiology market, and the successful adoption of these emerging products will result in significant market growth rate.

Complex purchasing systems also hinder the adoption of interventional cardiac devices, particularly in Asia-Pacific (APAC). In this increasingly competitive market, APAC countries face an alarming rise in cardiovascular disorders and account for half of the global burden of diseases. This situation will likely worsen during the next few years, as the region has an ageing population with an increasingly unhealthy lifestyle.

Another challenge peculiar to the region is caused by heavy subsidization of healthcare by governments. Lower costs heighten hospitalization rates, and, in turn, healthcare costs, severely impact the economy and the market.

"Nevertheless, the urgent requirement to decrease hospital stay times is driving minimally invasive interventional procedures, which ensure quick recovery and lower risk of complications," noted Allada. "As minimally invasive interventional cardiac procedures become the solution of choice among patients and the medical fraternity, demand for interventional cardiac devices will grow."

Acquiring added capabilities and expanding capacity through long-term strategic partnerships will be crucial for device manufacturers. Repositioning product and service offerings to enhance value for clients will help strengthen their foothold in this dynamic landscape.

The Global Emerging Interventional Cardiac Devices Market is part of the Advanced Medical Technologies (http://www.medtech.frost.com), Growth Partnership Service program. Frost & Sullivan's related studies include: Disinfection and Sterilization Equipment Market Trends in Asia-Pacific, US Hand Hygiene Market, 2013 Global Medical Devices Outlook, and Endoscopy Devices Market in Australia, South Korea, and Southeast Asia. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

The Global Emerging Interventional Cardiac Devices Market
ND01-54

Contact:
Jennifer Carson
Corporate Communications – North America
P: 210.247.2450
E: [email protected]

LinkedIn: Transform Health Group 
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan

http://www.frost.com

SOURCE Frost & Sullivan